Mane Yogita L,
Vishal Babar,
Sudarshan Nagrale,
- Research Scholar, Department of Pharmacy, Dattakala College of Pharmacy, Pune, Maharashtra, India
- Associate Professor, Department of Pharmacy, Dattakala College of Pharmacy, Pune, Maharashtra, India
- Assistant Professor, Department of Pharmacy, Dattakala College of Pharmacy, Pune, Maharashtra, India
Abstract
Cancer remains one of the leading causes of mortality worldwide despite significant advances in diagnosis and treatment. The clinical usefulness of many anticancer drugs is often restricted by toxicity, poor selectivity, and the emergence of drug resistance. These limitations have encouraged the search for novel heterocyclic compounds with improved therapeutic efficacy and safety. Among these, the 1,3,4-thiadiazole scaffold has gained considerable attention because of its favorable physicochemical characteristics, metabolic stability, and ability to interact with multiple biological targets. Various 1,3,4-thiadiazole derivatives have demonstrated potent anticancer activity by inducing apoptosis, arresting the cell cycle, inhibiting angiogenesis, and modulating important signaling pathways involved in tumor progression. Structural modification and molecular hybridization have further enhanced their pharmacological potential. This review summarizes recent advances in the chemistry, design strategies, synthetic approaches, structure–activity relationships, and anticancer applications of 1,3,4-thiadiazole derivatives. In addition, current challenges and future perspectives associated with the development of thiadiazole-based anticancer agents are briefly discussed.
Keywords: 1,3,4-Thiadiazole, Anticancer Agents, Medicinal Chemistry, Drug Design, Structure–Activity Relationship, Cancer Therapy
References
1. Indelicato S, Bongiorno D, Mauro M, Cascioferro S. Recent Developments of 1.3.4-Thiadiazole Compounds as Anticancer Agents. Pharmaceuticals 2025;18(4):580. doi:10.3390/ph18040580
2. Janowska S, Paneth A, Wujec M. Cytotoxic Properties of 1,3,4-Thiadiazole Derivatives–A Review. Molecules. 2020;25(18):4309. doi: 10.33907 molecules25184309.
3. Jampilek J. Heterocycles in Medicinal Chemistry. Molecules. 2019; 24:3839 Doi: 10.3390/molecules24213839.
4. LiY, Geng I, Liu Y., Yu S., Zhao G. Thiadiazole –A Promising Structure in Medicinal Chemistry. ChemMedChem. 2013:8:27-41. Doi: 10.1002 cmdc.201200355.
5. Kumar D., Kumar H., Kumar V., Deep A., Sharma A. Marwaha M.G. Marwaha R.K Mechanism-Based Approaches of 1,3,4 Thiadiazole Scaffolds as Potent Enzyme Inhibitors for Cytotoxicity and Antiviral Activity. Med. Drug Discov. 2023; 17:100150. Doi: 10.1016/i.medidd.2022.100150
6. El-Masry R.M., Essa B.M., Selim A.A., El- Emam S.Z. Mohamed K.0., Sakr T.M Kadry H.H. Taher A.T. Abou-Seri S.M. New 5-Aryl 1,3,4-Thiadiazole-Based Anticancer Agents: Design, Synthesis, In Vitro Biological Evaluation and In Vivo Radioactive Tracing Studies. Pharmaceuticals. 2022:15:1476. doi| 10.3390/ph15121476.
7. Abouzeid A.S., Al-Humaidi T.Y., Bazaid A.S. Qanash H. Binsaleh N.K., Alamri 4., Ibrahim S.M., Gomha S.M. Synthesis, Molecular Docking Study, and Cytotoxicity Evaluation of Some Novel 1.3.4-Thiadiazole as Well as 1.3-Thiazole Derivatives Bearing a Pyridine Moiety. Molecules. 2022:27:6368. doit 10.3390/molecules27196368.
8. Alsehli M., Aliuhani A., Ihmaid S.K., El- Messery S.M., Othman D.I.A. El-Sayed A.-A.A.A. Ahmed H.E.A., Rezki N. Aouad M.R. Design and Synthesis of Benzene Homologues Tethered with 1,2,4-Triazole and 1,3,4-Thiadiazole Motifs Revealing Dual MCF-7/HepG2 Cytotoxic Activity with Prominent Selectivity via Histone Demethylase LSD1 Inhibitory Effect. Int. J. Mol Sci 2022; 23:8796. doi: 10.3390/ijms23158796.
9. Kang J.-x., Li C., Cheng Y.-M., Huang M.-x. Zhao G.-K., Jin Z.-L., Qi X.-W., Gu J., Ouvang O Advances in Small-Molecule Dual Inhibitors Targetina EGFR and HER2 Receptors as Anti- Cancer Agents. Curr. Med. Chem. 2024 doi: 10.2174/0109298673308896240528173317. ahead of print.
10. LiX.-Y. Wang D.-P., Li S., Xue W.-H., Qian X.- H. Liu K.-L. Li Y.-H. Lin Q.-Q. Dong G., Meng F.- H., et al. Discovery of N-(1,3,4-Thiadiazol-2- Yl) Benzamide Derivatives Containing a 6,7- Methoxyquinoline Structure as Novel EGFR/ HER-2 Dual-Target Inhibitors against Cancer Growth and Angiogenesis Bioorg. Chem. 2022; 119:105469. doi: 10.1016/j.bioorg.2021.105469.
11. Serag M.l., Tawfik S.S., Eisa H.M., Badr S.M.I Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4- Thiadiazole-Based Compounds as EGFR Inhibitors. Drug Dev. Res. 2025;86: e70035. doi 10.1002, ddr.70035.
12. Hekal M.H., Farag P.S., Hemdan M.M. El- Saved A.A., Hassaballah A.1., El- Saved W.M. New 1,3,4-Thiadiazoles as Potential Anticancer Agents: Pro- Apoptotic, Cell Cycle Arrest, Molecular Modelling, and ADMET Profile. RSC Adv. 2023:13:1581015825. doi:
10.1039/D3RA02716C.
13. Żurawska K., Stokowy M., Kapica P., Olesiejuk M., Kudelko A., Papaj K. Skonieczna M., Szeja W., Walczak K., Kasprzycka A. Synthesis and Preliminary Anticancer Activity Assessment of N-Glycosides of 2-Amino-1,3,4- Thiadiazoles. Molecules. 202 1:26: 7245.doi 10.3390/molecules26237245.
14. Stecoza C.E. Nitulescu G.M. Draghici C. Caproiu M.T., Hanganu A., Olaru O.T., Mihai D.P., Bostan M. Mihaila M. Synthesis of 1,3,4- Thiadiazole Derivatives and Their Anticancer Evaluation. Int. J. Mol. Sci. 2023; 24:17476. doi: 10.3390 ijms242417476.
15. Janowska S. Khylyuk D., Bielawska A. Szymanowska A., Gornowicz A., Bielawski K. Noworól J., Mandziuk S., Wujec M. New 1,3,4- Thiadiazole Derivatives with Anticancer Activity. Molecules. 2022: 27:1814. doi: 10.3390 molecules2706 1814.
16. Oubella A., Bimoussa A., Rehman M.T. AlAjmi M.F., Auhmani A., Taha M.L. Morjani H. Itto M.Y.A. Molecular Hybrids Based on 1,2,3- Triazole and 1,3,4- Thiadiazole Cores: Synthesis, Characterization, Anticancer Activity and in Silico Study. J. Mol. Struct. 2024; 13 11:138339. doi: 10.10167 j. molstruc.2024.138339.
17. Cascioferro S. Li Petri G. Parrino B. El Hassouni B. Carbone D. Arizza V. Perricone U. Padova A. Funel N. Peters G.J., et al. 3-(6- Phenylimidazo [2, 1-b] [1,3,4] Thiadiazole-2-Y1)-1H- Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Molecules 2020:25:329. doi:
10.3390/molecules25020329
18. Noce B. Di Bello E. Fioravanti R. Mai A. LSD1 Inhibitors for Cancer Treatment: Focus on Multi-Target Agents and Compounds in Clinical Trials. Front. Pharmacol. 2023:14:112091 1. doi: 10.3389/fphar.2023.1120911.
Research & Reviews: A Journal of Drug Design & Discovery
| Volume | 13 | |
| 02 | ||
| Received | 11/07/2026 | |
| Accepted | 20/07/2026 | |
| Published | 26/07/2026 | |
| Publication Time | 15 Days |